Drugs / Autologous CAR123 T lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06765876 | Oct 2024 → Dec 2028 expected | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia, myelodysplastic syndrome, precursor lymphoblastic lymphoma/leukemia | Institute of Hematology and Blood Transfusion, Czech Republic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CAR123 T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06765876 ↗ |
| Modality | Cell therapy | “Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)” NCT06765876 ↗ |